Logo

thyroid cancer

Eli Lilly to Share With Regulators Data on Retevmo Besting Standard Drugs in Thyroid Cancer Patients

The Phase III study data showing Retevmo improved progression-free survival in patients with RET-mutant tumors may support conversion from accelerated to full approval. 

Roche, Blueprint Medicines Withdraw Gavreto in RET-Mutant Medullary Thyroid Cancer in US

Genentech has decided it will no longer pursue the confirmatory trial for Gavreto in this setting due to feasibility.

Roche to Terminate Gavreto Deal With Blueprint Medicines

Blueprint will regain global commercialization rights for the RET inhibitor following Roche's decision to end the collaboration for strategic reasons.

Geisinger Offering Prophylactic Thyroidectomy to Patients with Cancer-Linked RET Variants
Premium

While Geisinger sees value in identifying at-risk patients and diagnosing cancer early, some experts are concerned about overtreatment.

OncoDNA, Eli Lilly Partner on Thyroid Cancer Biomarker Testing

The companies are working together to offer next-generation sequencing-based molecular testing on thyroid cancer biopsies to clinicians in Italy.

Sep 27, 2022

Thermo Fisher Gets FDA OK for CDx Test to Guide Use of Lilly Drug in Lung, Thyroid Cancers

Feb 25, 2022

Duke Cancer Institute Expanding Molecular Tumor Board Access to Rural, Underserved Communities
Premium

Feb 11, 2022

Seattle Cancer Care Alliance Aims to Improve Molecular Profiling Access for Thyroid Cancer Patients
Premium

Feb 4, 2022

CHOP Researchers Find Gene Fusions are Harbingers of Aggressive Disease in Pediatric Thyroid Cancer
Premium

Jan 31, 2022

CMS No Longer Reimbursing Interpace Bio Thyroid Tests; Firm's Rights Offering Terminated

Dec 7, 2021

Pan-Cancer Analysis Reveals Unique Features in Tumors From Younger People

Oct 8, 2021

AffyImmune Raises $30M in Series A Funding to Advance Solid Tumor CAR T-Cell Therapy

Oct 1, 2021

UK's NICE Recommends Selpercatinib for RET-Altered Thyroid Cancers Through Cancer Drugs Fund

Apr 6, 2021

Turning Point Therapeutics Shares Initial Data on RET Inhibitor, Anticipates FDA Meeting

Mar 11, 2021

Fore Biotherapeutics Enters Pharma Business With BRAF Inhibitor as Lead Product
Premium

Dec 22, 2020

Bayer, Veracyte to Identify Therapy-Resistant Thyroid Cancer Patients

Dec 10, 2020

Tempus Raises $200M in Series G2, Inks Oncology Testing Collaboration With Bayer

Dec 2, 2020

Genentech, Blueprint Medicines' Gavreto Receives FDA Approval in RET-Altered Thyroid Cancer
Premium

Jul 14, 2020

Roche to Pay $775M to Blueprint Medicines for Rights to Pralsetinib for RET-Altered Tumors

Jul 1, 2020

Blueprint Medicines Files NDA for Pralsetinib for RET-Driven Thyroid Cancers

Jun 10, 2020

Bayer Continuing Vitrakvi Studies to Improve Understanding of Activity In Specific Tumor Types
Premium

Jun 9, 2020

NeoGenomics, Lilly Oncology Partner for Thyroid Cancer Testing Program

Jun 5, 2020

Secondary Tumor Risk in Pediatric Cancer Survivors Linked to Germline Variants, Treatment Type

Jun 2, 2020

Blueprint's Positive Pralsetinib Data Places New Option on Horizon for RET-Altered Cancer Patients
Premium

May 11, 2020

FDA Approves Lilly's Retevmo for RET-Driven Lung, Thyroid Cancers